Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by SupplyChainGuruon Jan 14, 2011 10:34am

476 Views

Post# 17971897

RE: now we know

Agreed. A quick and dirty manipulation trick, most probably engineered by anybody you see buying as of this morning.

That said, while no one cant deny the dilution process, this stock should make a decent jump to .18-.22 by first week of Feb when the tax deadline passes and more results are shared.

For those who bought the stock at 0.13ish, that would a smart, safe time to sell. Waiting any longer is a bit risky, but hey like you said, it is a circus out there and you never know what theyre really hiding from us.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale